Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

188.31 +3.30 (+1.78%)

Streaming Delayed Price Updated: 10:36 AM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity ↗

May 25, 2023

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical...

Via Benzinga

World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients ↗

May 25, 2023

Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project...

Via Benzinga

Where Jazz Pharmaceuticals Stands With Analysts ↗

May 15, 2023

Via Benzinga

Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income? ↗

May 11, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022.

Via Benzinga

Recap: Jazz Pharmaceuticals Q1 Earnings ↗

May 10, 2023

Via Benzinga

Axsome's New Drug Is Scoring a Win. Is the Stock a Buy? ↗

May 09, 2023

The biotech's share price more than doubled during last year's bear market.

Via The Motley Fool

Why Avadel Pharma Shares Are Gaining Today ↗

May 01, 2023

Via Benzinga

The Latest Analyst Ratings for Jazz Pharmaceuticals ↗

March 06, 2023

Via Benzinga

Earnings Scheduled For March 1, 2023 ↗

March 01, 2023

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

Via Benzinga

Earnings Preview For Jazz Pharmaceuticals ↗

February 28, 2023

Via Benzinga

GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation ↗

May 09, 2023

Blood cancers such as AML, MM, and MDS affect a terrible toll on patients and their loved ones. Glycomimetics may be such a company that can offer patients suffering from various blood cancers hope...

Via Talk Markets

Pressure BioScience's Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux ↗

May 09, 2023

Often considered recession-proof, the life sciences sector faced a surprising amount of uncertainty over the past few years with up to 80% of companies saying they’ve been negatively impacted by the...

Via Benzinga

Why Shares of Avadel Soared This Week ↗

May 05, 2023

The company got its first FDA approval.

Via The Motley Fool

If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now ↗

April 25, 2023

Axsome's new products have blockbuster potential.

Via The Motley Fool

The Top Healthcare Stocks to Buy With $100 ↗

April 18, 2023

A small investment now may bring big results over time.

Via The Motley Fool

The Global Cannabis Pharmaceuticals Market Size Is Expected To Surpass $125 Billion by 2028

April 11, 2023

EQNX::TICKER_START (OTCQX:TCNNF),(OTCQX:CURLF),(NASDAQ:TLRY),(NASDAQ:JAZZ) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Cannabis

2 Top Biotech Stocks to Buy in April ↗

April 04, 2023

Right now you can pick up these stocks on the dip.

Via The Motley Fool

The 3 Best Growth Stocks to Buy in the Biotech Sector ↗

March 29, 2023

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Via InvestorPlace

Is Big Pharma Coming For Your Cannabis Business? ↗

March 27, 2023

Cannabis stocks have struggled in the market in recent years as the industry push to gain ground on the regulatory front hasn't progressed as quickly as investors had hoped. Yet beverage companies...

Via Benzinga

My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years ↗

March 21, 2023

The cannabis sector has been disappointing in recent years, but this company stands out.

Via The Motley Fool

Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain ↗

March 14, 2023

Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK.

Via Benzinga

Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries ↗

March 14, 2023

Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue.

Via Benzinga

Zymeworks Offers Hope for More than Just Long-Term Investors

March 09, 2023

Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher

Via MarketBeat

With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path ↗

March 08, 2023

The global CBD market is on an upward trajectory, and there are no indications that the growth could be slowing down anytime soon. The market was valued at $5.18 billion in 2021 and is expected to...

Via Benzinga

Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying ↗

March 07, 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various...

Via Benzinga

Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains ↗

March 02, 2023

It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers...

Via Benzinga

Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook ↗

March 02, 2023

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights

Via Benzinga

Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says ↗

February 17, 2023

The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis.

Via Benzinga

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling ↗

February 13, 2023

The company only just gained approval for its depression drug in August.

Via Investor's Business Daily

GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow ↗

February 13, 2023

Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of...

Via Talk Markets

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.